{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:54:23Z","timestamp":1781636063774,"version":"3.54.5"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA269231"],"award-info":[{"award-number":["R01 CA269231"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>CAR T-cell therapy is a transformative immunotherapy for pediatric patients with relapsed or refractory malignancies. Imaging plays a crucial role in evaluating treatment efficacy and detecting complications. This review provides time-specific guidance for radiologists on the imaging findings before and after CAR T-cell infusion and highlights how imaging supports clinical decision-making across the treatment course. Pre-treatment imaging at baseline focuses on ruling out active infection and quantifying residual tumor burden. In addition, quantitative imaging biomarkers can predict tumor response and toxicity risk. Between day 0\u201328 after CAR T-cell infusion, imaging is primarily performed to detect side effects, such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). At day\u2009+\u200928, imaging provides early assessment of tumor response. Radiologists must recognize atypical immune-related response patterns at this time, including pseudoprogression and, less commonly, hyperprogression. Beyond day 28, imaging monitors for late side effects and infections, while also documenting ongoing tumor response or recurrence. Familiarity with these time-specific imaging patterns and pitfalls, coupled with knowledge of quantitative biomarkers, enables radiologists to differentiate toxicity from therapeutic effect, avoid misclassification of early immune-related changes, and optimize outcomes in pediatric CAR T-cell therapy.<\/jats:p>","DOI":"10.1186\/s40644-026-01004-0","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:34:07Z","timestamp":1770914047000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Imaging the efficacy and side effects of CAR T-cell therapy in children and young adults"],"prefix":"10.1186","volume":"26","author":[{"given":"Iryna","family":"Vasyliv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra Shokri","family":"Varniab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashi B.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Johns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Ramakrishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike E.","family":"Daldrup-Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"issue":"8","key":"1004_CR1","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen Receptor\u2013Modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725\u201333.","journal-title":"N Engl J Med"},{"issue":"4","key":"1004_CR2","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-18-2035","volume":"25","author":"MC O\u2019Leary","year":"2019","unstructured":"O\u2019Leary MC, Lu X, Huang Y, Lin X, Mahmood I, Przepiorka D, et al. FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res. 2019;25(4):1142\u20136.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"1004_CR3","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1200\/JCO.19.03279","volume":"38","author":"NN Shah","year":"2020","unstructured":"Shah NN, Highfill SL, Shalabi H, Yates B, Jin J, Wolters PL, et al. CD4\/CD8 T-Cell selection affects chimeric antigen receptor (CAR) T-Cell potency and toxicity: updated results from a phase I Anti-CD22 CAR T-Cell trial. J Clin Oncol. 2020;38(17):1938\u201350.","journal-title":"J Clin Oncol"},{"issue":"13","key":"1004_CR4","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","volume":"4","author":"CC Pinnix","year":"2020","unstructured":"Pinnix CC, Gunther JR, Dabaja BS, Strati P, Fang P, Hawkins MC, et al. Bridging therapy prior to Axicabtagene Ciloleucel for relapsed\/refractory large B-cell lymphoma. Blood Adv. 2020;4(13):2871\u201383.","journal-title":"Blood Adv"},{"issue":"1","key":"1004_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0b013e3181b88ffc","volume":"33","author":"C Wrzesinski","year":"2010","unstructured":"Wrzesinski C, Paulos CM, Kaiser A, Muranski P, Palmer DC, Gattinoni L, et al. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother. 2010;33(1):1\u20137.","journal-title":"J Immunother"},{"issue":"17","key":"1004_CR6","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","volume":"133","author":"AV Hirayama","year":"2019","unstructured":"Hirayama AV, Gauthier J, Hay KA, Voutsinas JM, Wu Q, Gooley T, et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood. 2019;133(17):1876\u201387.","journal-title":"Blood"},{"issue":"9","key":"1004_CR7","first-page":"876","volume":"30","author":"W Wesson","year":"2024","unstructured":"Wesson W, Dima D, Suleman N, Saif MSI, Tabak C, Logan E, et al. Timing of toxicities and Non-Relapse mortality following CAR T therapy in myeloma. Transpl Cell Ther. 2024;30(9):876\u201384.","journal-title":"Transpl Cell Ther"},{"issue":"11","key":"1004_CR8","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1182\/blood.2024025910","volume":"145","author":"MS Nair","year":"2025","unstructured":"Nair MS, Silbert SK, Rejeski K, Wilson KA, Lamble AJ, Valtis Y, et al. Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia. Blood. 2025;145(11):1136\u201348.","journal-title":"Blood"},{"issue":"8","key":"1004_CR9","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1007\/s00259-024-06667-0","volume":"51","author":"J Gui","year":"2024","unstructured":"Gui J, Li M, Xu J, Zhang X, Mei H, Lan X. [18F]FDG PET\/CT for prognosis and toxicity prediction of diffuse large B-cell lymphoma patients with chimeric antigen receptor T-cell therapy. Eur J Nucl Med Mol Imaging. 2024;51(8):2308\u201319.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1004_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41408-023-00895-7","volume":"13","author":"WG Breen","year":"2023","unstructured":"Breen WG, Young JR, Hathcock MA, Kowalchuk RO, Thorpe MP, Bansal R, et al. Metabolic PET\/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity. Blood Cancer J. 2023;13(1):127.","journal-title":"Blood Cancer J"},{"issue":"1","key":"1004_CR11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40644-022-00513-y","volume":"22","author":"T Sj\u00f6holm","year":"2022","unstructured":"Sj\u00f6holm T, Korenyushkin A, Gammelg\u00e5rd G, Sar\u00e9n T, L\u00f6vgren T, Loskog A, et al. Whole body FDG PET\/MR for progression free and overall survival prediction in patients with relapsed\/refractory large B-cell lymphomas undergoing CAR T-cell therapy. Cancer Imaging. 2022;22(1):76.","journal-title":"Cancer Imaging"},{"issue":"1","key":"1004_CR12","doi-asserted-by":"publisher","first-page":"e70029","DOI":"10.1002\/hon.70029","volume":"43","author":"E Galli","year":"2025","unstructured":"Galli E, Guarneri A, Sor\u00e0 F, Viscovo M, Pansini I, Maiolo E, et al. Baseline tumor burden assessed with AI-Guided PET\/CT total metabolic tumor volume (TMTV) and LDH levels predict efficacy of CAR-T in aggressive B-Cell lymphoma. Hematol Oncol. 2025;43(1):e70029.","journal-title":"Hematol Oncol"},{"key":"1004_CR13","doi-asserted-by":"publisher","first-page":"713577","DOI":"10.3389\/fonc.2021.713577","volume":"11","author":"R Hong","year":"2021","unstructured":"Hong R, Tan Su Yin E, Wang L, Zhao X, Zhou L, Wang G, et al. Tumor burden measured by 18F-FDG PET\/CT in predicting efficacy and adverse effects of chimeric antigen receptor T-Cell therapy in Non-Hodgkin lymphoma. Front Oncol. 2021;11:713577.","journal-title":"Front Oncol"},{"issue":"1","key":"1004_CR14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1158\/1078-0432.CCR-23-1561","volume":"30","author":"JP Alderuccio","year":"2024","unstructured":"Alderuccio JP, Reis IM, Hamadani M, Nachiappan M, Leslom S, Kahl BS, et al. PET\/CT biomarkers enable risk stratification of patients with Relapsed\/Refractory diffuse large B-cell lymphoma enrolled in the LOTIS-2 clinical trial. Clin Cancer Res. 2024;30(1):139\u201349.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1004_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","volume":"131","author":"JA Hill","year":"2018","unstructured":"Hill JA, Li D, Hay KA, Green ML, Cherian S, Chen X, et al. Infectious complications of CD19-targeted chimeric antigen receptor\u2013modified T-cell immunotherapy. Blood. 2018;131(1):121\u201330.","journal-title":"Blood"},{"issue":"4","key":"1004_CR16","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","volume":"25","author":"N Frey","year":"2019","unstructured":"Frey N, Porter D. Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl. 2019;25(4):e123\u20137.","journal-title":"Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl"},{"issue":"6","key":"1004_CR17","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24(6):739\u201348.","journal-title":"Nat Med"},{"issue":"21","key":"1004_CR18","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy. Blood. 2017;130(21):2295\u2013306.","journal-title":"Blood"},{"issue":"4","key":"1004_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3348\/kjr.2023.1100","volume":"25","author":"JS Ko","year":"2024","unstructured":"Ko JS, Lee JH, Yoon DH, Suh CH, Chung SR, Choi YJ, et al. CT demonstration of local Cytokine-Release syndrome involving the head and neck following chimeric antigen receptor T cell infusion therapy. Korean J Radiol. 2024;25(4):399\u2013402.","journal-title":"Korean J Radiol"},{"issue":"1","key":"1004_CR20","doi-asserted-by":"publisher","first-page":"e05209","DOI":"10.1002\/ccr3.5209","volume":"10","author":"RM Mart\u00edn-Rojas","year":"2022","unstructured":"Mart\u00edn-Rojas RM, G\u00f3mez\u2010Centuri\u00f3n I, Bail\u00e9n R, Bastos M, Diaz\u2010Crespo F, Carbonell D, et al. Hemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS) following treatment with tisagenlecleucel. Clin Case Rep. 2022;10(1):e05209.","journal-title":"Clin Case Rep"},{"issue":"1","key":"1004_CR21","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/neuonc\/noaa183","volume":"23","author":"NG Holtzman","year":"2021","unstructured":"Holtzman NG, Xie H, Bentzen S, Kesari V, Bukhari A, El Chaer F, et al. Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes. Neuro-Oncol. 2021;23(1):112\u201321.","journal-title":"Neuro-Oncol"},{"issue":"9","key":"1004_CR22","doi-asserted-by":"publisher","first-page":"5206","DOI":"10.1007\/s00330-025-11515-2","volume":"35","author":"HG Kim","year":"2025","unstructured":"Kim HG, Yeom KW, Vasyliv I, Shokri Varniab Z, Erickson C, Baggott C, et al. Brain MRI changes in children and young adults with B-cell acute lymphoblastic leukemia following chimeric antigen receptor T-cell therapy. Eur Radiol. 2025;35(9):5206\u201316.","journal-title":"Eur Radiol"},{"key":"1004_CR23","doi-asserted-by":"crossref","unstructured":"Jonathan H, Grace L, Daniel C, Laura M, Emma T, Bawani A et al. Immune effector cell-associated neurotoxicity syndrome (ICANS) secondary to CAR T-cell therapy: experience from a single centre. In: Association of British Neurologists: Annual Meeting Abstracts 2023 [Internet]. BMJ Publishing Group Ltd; 2023 [cited 2025 Oct 28]. p. A8.1-A8. Available from: https:\/\/jnnp.bmj.com\/lookup\/doi\/.","DOI":"10.1136\/JNNP-2023-ABN.22"},{"key":"1004_CR24","doi-asserted-by":"publisher","first-page":"634445","DOI":"10.3389\/fonc.2021.634445","volume":"11","author":"BD Brown","year":"2021","unstructured":"Brown BD, Tambaro FP, Kohorst M, Chi L, Mahadeo KM, Tewari P, et al. Immune effector cell associated neurotoxicity (ICANS) in pediatric and young adult patients following chimeric antigen receptor (CAR) T-Cell therapy: can we optimize early diagnosis? Front Oncol. 2021;11:634445.","journal-title":"Front Oncol"},{"issue":"1","key":"1004_CR25","doi-asserted-by":"publisher","first-page":"e30741","DOI":"10.1002\/pbc.30741","volume":"71","author":"H Shalabi","year":"2024","unstructured":"Shalabi H, Harrison C, Yates B, Calvo KR, Lee DW, Shah NN. Intrathecal hydrocortisone for treatment of children and young adults with CAR T-cell immune\u2010effector cell\u2010associated neurotoxicity syndrome. Pediatr Blood Cancer. 2024;71(1):e30741.","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"1004_CR26","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8(8):958\u201371.","journal-title":"Cancer Discov"},{"issue":"7","key":"1004_CR27","doi-asserted-by":"publisher","first-page":"e214086","DOI":"10.1212\/WNL.0000000000214086","volume":"105","author":"JL McGuire","year":"2025","unstructured":"McGuire JL, Pinto S, Erdogan EN, Li Y, Bhatia A, Oztek MA, et al. Neuroimaging findings in children and young adults with neurotoxicity after CAR T-Cell therapy for B-Cell malignancies. Neurology. 2025;105(7):e214086.","journal-title":"Neurology"},{"issue":"11","key":"1004_CR28","doi-asserted-by":"publisher","first-page":"e28635","DOI":"10.1002\/pbc.28635","volume":"67","author":"AP Tan","year":"2020","unstructured":"Tan AP. CAR T-cell therapy-related neurotoxicity in paediatric acute lymphocytic leukaemia. Pediatr Blood Cancer. 2020;67(11):e28635.","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"1004_CR29","first-page":"1263","volume":"26","author":"WE Reddick","year":"2005","unstructured":"Reddick WE, Glass JO, Helton KJ, Langston JW, Xiong X, Wu S, et al. Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate. AJNR Am J Neuroradiol. 2005;26(5):1263\u20139.","journal-title":"AJNR Am J Neuroradiol"},{"key":"1004_CR30","doi-asserted-by":"publisher","first-page":"1639892","DOI":"10.3389\/fonc.2025.1639892","volume":"15","author":"RD Agarwal","year":"2025","unstructured":"Agarwal RD, Kunwor R, Sudanagunta K. Posterior reversible encephalopathy syndrome after CD19 chimeric antigen receptor therapy for B-acute lymphoblastic leukemia: case report. Front Oncol. 2025;15:1639892.","journal-title":"Front Oncol"},{"issue":"7supplement1","key":"1004_CR31","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1212\/WNL.0000000000204579","volume":"102","author":"HM Khanli","year":"2024","unstructured":"Khanli HM. An unusual case of transverse myelitis after Anti-CD19 CAR T cell therapy for a patient with diffuse large B cell lymphoma (P6-5.006). Neurology. 2024;102(7supplement1):2513.","journal-title":"Neurology"},{"issue":"1","key":"1004_CR32","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/jha2.286","volume":"3","author":"S Sheikh","year":"2022","unstructured":"Sheikh S, Mokhtari S, Silverman JA, Reid K, Faramand R, Davila ML, et al. Transverse myelitis after anti-CD19 directed CAR T cell therapy for relapsed large B cell lymphoma. eJHaem. 2022;3(1):223\u20137.","journal-title":"eJHaem"},{"issue":"4","key":"1004_CR33","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/bjh.19015","volume":"203","author":"EC Andrew","year":"2023","unstructured":"Andrew EC, Hughes D, Gilsenan M, Mignone C, Khaw SL, Wang SS. Severe persistent neurotoxicity associated with CAR T therapy in children. Br J Haematol. 2023;203(4):651\u20135.","journal-title":"Br J Haematol"},{"issue":"1","key":"1004_CR34","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40644-023-00566-7","volume":"23","author":"M Winkelmann","year":"2023","unstructured":"Winkelmann M, Blumenberg V, Rejeski K, B\u00fccklein VL, Ingenerf M, Unterrainer M, et al. Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteria. Cancer Imaging. 2023;23(1):44.","journal-title":"Cancer Imaging"},{"issue":"8","key":"1004_CR35","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.2967\/jnumed.125.269670","volume":"66","author":"A Farolfi","year":"2025","unstructured":"Farolfi A, Casadei B, Malizia C, Ussia R, Rocchi V, Paccagnella A, et al. Semiquantitative PET parameters refine prognosis in CAR T\u2013Treated lymphoma after 1 and 3 months: A prospective Single-Center study. J Nucl Med. 2025;66(8):1183\u201391.","journal-title":"J Nucl Med"},{"issue":"10","key":"1004_CR36","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.clml.2023.06.005","volume":"23","author":"F Lutfi","year":"2023","unstructured":"Lutfi F, Goloubeva O, Kowatli A, Gryaznov A, Kim DW, Dureja R, et al. Imaging biomarkers to predict outcomes in patients with large B-Cell lymphoma with a day 28 partial response by 18F-FDG PET\/CT imaging following CAR-T therapy. Clin Lymphoma Myeloma Leuk. 2023;23(10):757\u201363.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"1004_CR37","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1182\/bloodadvances.2021006715","volume":"6","author":"A Al Zaki","year":"2022","unstructured":"Al Zaki A, Feng L, Watson G, Ahmed SA, Mistry H, Nastoupil LJ, et al. Day 30 SUVmax predicts progression in patients with lymphoma achieving PR\/SD after CAR T-cell therapy. Blood Adv. 2022;6(9):2867\u201371.","journal-title":"Blood Adv"},{"issue":"8","key":"1004_CR38","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/RLU.0000000000003756","volume":"46","author":"P Sesques","year":"2021","unstructured":"Sesques P, Tordo J, Ferrant E, Safar V, Wallet F, Dhomps A, et al. Prognostic impact of 18F-FDG PET\/CT in patients with aggressive B-Cell lymphoma treated with Anti-CD19 chimeric antigen receptor T cells. Clin Nucl Med. 2021;46(8):627\u201334.","journal-title":"Clin Nucl Med"},{"issue":"1","key":"1004_CR39","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3324\/haematol.2021.280550","volume":"108","author":"J Galtier","year":"2022","unstructured":"Galtier J, Vercellino L, Chartier L, Olivier P, Tabouret-Viaud C, Mesguich C, et al. Positron emission tomography-imaging assessment for guiding strategy in patients with relapsed\/refractory large B-cell lymphoma receiving CAR T cells. Haematologica. 2022;108(1):171\u201380.","journal-title":"Haematologica"},{"issue":"22","key":"1004_CR40","doi-asserted-by":"publisher","first-page":"6990","DOI":"10.1182\/bloodadvances.2023011399","volume":"7","author":"EC Liang","year":"2023","unstructured":"Liang EC, Albittar A, Huang JJ, Hirayama AV, Kimble EL, Portuguese AJ, et al. Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed\/refractory CLL. Blood Adv. 2023;7(22):6990\u20137005.","journal-title":"Blood Adv"},{"issue":"1","key":"1004_CR41","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s12149-020-01544-w","volume":"35","author":"T Derlin","year":"2021","unstructured":"Derlin T, Schultze-Florey C, Werner RA, M\u00f6hn N, Skripuletz T, David S, et al. 18F-FDG PET\/CT of off-target lymphoid organs in CD19-targeting chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma. Ann Nucl Med. 2021;35(1):132\u20138.","journal-title":"Ann Nucl Med"},{"issue":"1","key":"1004_CR42","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2967\/jnumed.117.193011","volume":"59","author":"L Dercle","year":"2018","unstructured":"Dercle L, Seban RD, Lazarovici J, Schwartz LH, Houot R, Ammari S, et al. 18F-FDG PET and CT scans detect new imaging patterns of response and progression in patients with hodgkin lymphoma treated by Anti\u2013Programmed death 1 immune checkpoint inhibitor. J Nucl Med. 2018;59(1):15\u201324.","journal-title":"J Nucl Med"},{"issue":"1","key":"1004_CR43","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/MNM.0b013e3283595cac","volume":"34","author":"K Pak","year":"2013","unstructured":"Pak K, Kim SJ, Kim IJ, Kim DU, Kim K, Kim H. Impact of cytokines on diffuse Splenic 18F-fluorodeoxyglucose uptake during positron emission tomography\/computed tomography. Nucl Med Commun. 2013;34(1):64\u201370.","journal-title":"Nucl Med Commun"},{"key":"1004_CR44","doi-asserted-by":"publisher","first-page":"745211","DOI":"10.3389\/fimmu.2021.745211","volume":"12","author":"J Liang","year":"2021","unstructured":"Liang J, Cao H, Wu B, Liu Y, He Y, Xu B, et al. Clinical value of 18F-FDG PET\/CT scan and cytokine profiles in secondary hemophagocytic lymphohistiocytosis in idiopathic inflammatory myopathy patients: A pilot study. Front Immunol. 2021;12:745211.","journal-title":"Front Immunol"},{"issue":"7","key":"1004_CR45","first-page":"e4381","volume":"29","author":"MR Hines","year":"2023","unstructured":"Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, et al. Immune effector Cell-Associated hemophagocytic Lymphohistiocytosis-Like syndrome. Transpl Cell Ther. 2023;29(7):e4381\u201343816.","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"1004_CR46","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13550-025-01201-1","volume":"15","author":"M Beck","year":"2025","unstructured":"Beck M, Blumenberg V, B\u00fccklein VL, Bundschuh RA, Harrer DC, Hirschb\u00fchl K, et al. Liver-FDG-uptake augments early PET\/CT prognostic value for CD19-targeted CAR-T cell therapy in diffuse large B cell lymphoma. EJNMMI Res. 2025;15(1):25.","journal-title":"EJNMMI Res"},{"issue":"1","key":"1004_CR47","doi-asserted-by":"publisher","first-page":"30360","DOI":"10.1038\/s41598-025-12630-2","volume":"15","author":"I Vasyliv","year":"2025","unstructured":"Vasyliv I, Kim HG, Erickson C, Baggott C, Schultz LM, Liang T, et al. Impact of CAR T cell therapy on thymus size in children and young adults with acute lymphoblastic leukemia. Sci Rep. 2025;15(1):30360.","journal-title":"Sci Rep"},{"issue":"11","key":"1004_CR48","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.3390\/jcm10112257","volume":"10","author":"AJ Lee","year":"2021","unstructured":"Lee AJ, Kim KW, Cho YC, Ko Y, Sung YS, Shin Y, et al. Incidence of immune-Mediated pseudoprogression of lymphoma treated with immune checkpoint inhibitors: systematic review and Meta-Analysis. J Clin Med. 2021;10(11):2257.","journal-title":"J Clin Med"},{"issue":"5","key":"1004_CR49","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/s41409-020-01156-y","volume":"56","author":"I Danylesko","year":"2021","unstructured":"Danylesko I, Shouval R, Shem-Tov N, Yerushalmi R, Jacoby E, Besser MJ, et al. Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma. Bone Marrow Transpl. 2021;56(5):1134\u201343.","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"1004_CR50","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.bbmt.2019.02.008","volume":"25","author":"J Wang","year":"2019","unstructured":"Wang J, Hu Y, Yang S, Wei G, Zhao X, Wu W, et al. Role of Fluorodeoxyglucose positron emission tomography\/Computed tomography in predicting the adverse effects of chimeric antigen receptor T cell therapy in patients with Non-Hodgkin lymphoma. Biol Blood Marrow Transpl. 2019;25(6):1092\u20138.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"1004_CR51","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/imt-2020-0188","volume":"13","author":"J Huang","year":"2021","unstructured":"Huang J, Rong L, Wang E, Fang Y. Pseudoprogression of extramedullary disease in relapsed acute lymphoblastic leukemia after CAR T-cell therapy. Immunotherapy. 2021;13(1):5\u201310.","journal-title":"Immunotherapy"},{"issue":"7","key":"1004_CR52","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1007\/s00259-022-05722-y","volume":"49","author":"D Cohen","year":"2022","unstructured":"Cohen D, Beyar-Katz O, Even-Sapir E, Perry C. Lymphoma pseudoprogression observed on [18F]FDG PET-CT scan 15 days after CAR-T infusion. Eur J Nucl Med Mol Imaging. 2022;49(7):2447\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1004_CR53","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1055\/s-0044-1787537","volume":"23","author":"S Guo","year":"2024","unstructured":"Guo S, Tan Z, Guan W, Yin Y. Early hyperprogression of rhabdomyosarcoma detected by 18F-FDG PET\/CT three weeks after CAR-T treatment. World J Nucl Med. 2024;23(3):212\u20136.","journal-title":"World J Nucl Med"},{"issue":"7","key":"1004_CR54","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1097\/RLU.0000000000004655","volume":"48","author":"G Wang","year":"2023","unstructured":"Wang G, Yang X, Wang H, Wang W, Yang J. New onset of tuberculosis complicating FDG PET\/CT evaluation in patient with recent chimeric antigen receptor T-Cell therapy. Clin Nucl Med. 2023;48(7):647\u20139.","journal-title":"Clin Nucl Med"},{"issue":"8046","key":"1004_CR55","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41586-024-08171-9","volume":"637","author":"M Monje","year":"2025","unstructured":"Monje M, Mahdi J, Majzner R, Yeom KW, Schultz LM, Richards RM, et al. Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. Nature. 2025;637(8046):708\u201315.","journal-title":"Nature"},{"issue":"1","key":"1004_CR56","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/ped4.12181","volume":"4","author":"X Xu","year":"2020","unstructured":"Xu X, Zhao W, Yue Z, Qin M, Jin M, Chang L, et al. 4SCAR-GD2\u2010modified T\u2010cell therapy in neuroblastoma with MYCN amplification: A case report with over 4\u2010year follow\u2010up data. Pediatr Investig. 2020;4(1):55\u20138.","journal-title":"Pediatr Investig"},{"issue":"5","key":"1004_CR57","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.21873\/anticanres.17032","volume":"44","author":"E Perrone","year":"2024","unstructured":"Perrone E, Taralli S, Pagliara D, Larocca LM, Vinti L, Leccisotti L. Breast relapse of pediatric B-Cell acute lymphoblastic leukemia after CAR-T therapy detected by18 F-FDG PET\/CT. Anticancer Res. 2024;44(5):2243\u20135.","journal-title":"Anticancer Res"},{"key":"1004_CR58","doi-asserted-by":"publisher","first-page":"1280007","DOI":"10.3389\/fimmu.2023.1280007","volume":"14","author":"W Mu","year":"2023","unstructured":"Mu W, Zhang M, Hu G, Han Y, Mao X, Chen C, et al. Case report: differential diagnosis of highly amplified anti-CD5 CAR T cells and relapsed lymphoma cells in a patient with refractory ALK positive anaplastic large cell lymphoma. Front Immunol. 2023;14:1280007.","journal-title":"Front Immunol"},{"issue":"5","key":"1004_CR59","doi-asserted-by":"publisher","first-page":"ofaa121","DOI":"10.1093\/ofid\/ofaa121","volume":"7","author":"SB Vora","year":"2020","unstructured":"Vora SB, Waghmare A, Englund JA, Qu P, Gardner RA, Hill JA. Infectious complications following CD19 chimeric antigen receptor T-cell therapy for Children, Adolescents, and young adults. Open Forum Infect Dis. 2020;7(5):ofaa121.","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"1004_CR60","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1007\/s00277-019-03755-2","volume":"98","author":"K Czy\u017cewski","year":"2019","unstructured":"for Polish Society of Pediatric Oncology and Hematology and Polish Society of Hematology and Blood Transfusion, Czy\u017cewski K, Styczy\u0144ski J, Giebel S, Fr\u0105czkiewicz J, Salamonowicz M, et al. Age-dependent determinants of infectious complications profile in children and adults after hematopoietic cell transplantation: lesson from the nationwide study. Ann Hematol. 2019;98(9):2197\u2013211.","journal-title":"Ann Hematol"},{"key":"1004_CR61","doi-asserted-by":"publisher","first-page":"1147454","DOI":"10.3389\/fcimb.2023.1147454","volume":"13","author":"P Zhang","year":"2023","unstructured":"Zhang P, Huang L, Zheng M, Zhang C, Wan D, Wei J, et al. Case report: active tuberculosis infection in CAR T-cell recipients post CAR T-cell therapy: a retrospective case series. Front Cell Infect Microbiol. 2023;13:1147454.","journal-title":"Front Cell Infect Microbiol"},{"issue":"10","key":"1004_CR62","first-page":"e1885","volume":"6","author":"K Kawata","year":"2023","unstructured":"Kawata K, Shima H, Shinjoh M, Yamazaki F, Kurosawa T, Yaginuma M, et al. Pneumocystis jirovecii pneumonia after CD4\u2009+\u2009T-cell recovery subsequent to CD19-targeted chimeric antigen receptor T-cell therapy: A case report and brief review of literature. Cancer Rep Hoboken NJ. 2023;6(10):e1885.","journal-title":"Cancer Rep Hoboken NJ"},{"issue":"6","key":"1004_CR63","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1097\/RLU.0000000000005759","volume":"50","author":"DL Gray","year":"2025","unstructured":"Gray DL, Fair J. FDG PET\/CT of atypical myeloid sarcoma after CAR T-Cell therapy. Clin Nucl Med. 2025;50(6):e362\u20134.","journal-title":"Clin Nucl Med"},{"issue":"3","key":"1004_CR64","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/s12185-023-03695-8","volume":"119","author":"K An","year":"2024","unstructured":"An K, He Y, Tang Y, Gu X, Qian J, Li B. Histiocytic sarcoma following CAR T-cell therapy: a case report. Int J Hematol. 2024;119(3):338\u201341.","journal-title":"Int J Hematol"},{"issue":"6","key":"1004_CR65","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1007\/s00432-020-03198-7","volume":"146","author":"J Du","year":"2020","unstructured":"Du J, Zhang Y. Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review. J Cancer Res Clin Oncol. 2020;146(6):1575\u201382.","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-026-01004-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01004-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01004-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:11:39Z","timestamp":1781633499000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40644-026-01004-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1004"],"URL":"https:\/\/doi.org\/10.1186\/s40644-026-01004-0","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This review article did not involve any new studies with human participants or animals performed by any of the authors. Ethical approval and consent to participate were therefore not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All authors agreed with the content of this manuscript and approved the submitted version.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}